{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:28:45Z","timestamp":1791354525970,"version":"4.3.1"},"reference-count":34,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2015,1,2]],"date-time":"2015-01-02T00:00:00Z","timestamp":1420156800000},"content-version":"unspecified","delay-in-days":10108,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infect. Control"],"published-print":{"date-parts":[[1987,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recent approval of ribavirin aerosol for the treatment of severe respiratory syncytial virus (RSV) in infants and young children is a significant addition to the antiviral drugs available today. When administered as an aerosolized form by face mask or mist tent for 20 to 21 hours per day, ribavirin effectively decreases the symptoms of RSV infection and the shedding of RSV virus.<\/jats:p><jats:p>Studies of other viral infections such as viral hepatitis, influenza A and B, Lassa fever, genital herpes, and herpes zoster have demonstrated promising, but inconclusive results. Further studies are needed to justify ribavirin therapy for these indications.<\/jats:p>","DOI":"10.1017\/s0195941700065978","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T04:58:40Z","timestamp":1470200320000},"page":"215-218","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Review of Ribavirin"],"prefix":"10.1017","volume":"8","author":[{"given":"Mark","family":"Eggleston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2015,1,2]]},"reference":[{"key":"S0195941700065978_ref034","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(84)90138-8"},{"key":"S0195941700065978_ref032","unstructured":"Cohen A : Chronic, oral administration of ribavirin in healthy adult male volunteers. Peninsular Testing Corp, North Miami, FL."},{"key":"S0195941700065978_ref030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198306163082403"},{"key":"S0195941700065978_ref029","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1985.03360210063030"},{"key":"S0195941700065978_ref027","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330430047028"},{"key":"S0195941700065978_ref026","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.2.200"},{"key":"S0195941700065978_ref025","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.3.309"},{"key":"S0195941700065978_ref023","doi-asserted-by":"publisher","DOI":"10.1159\/000237969"},{"key":"S0195941700065978_ref022","first-page":"43","volume-title":"Ribavirin: A Broad Spectrum Antiviral Agent","author":"Allen","year":"1980"},{"key":"S0195941700065978_ref021","first-page":"147","volume-title":"Ribavirin: A Broad Spectrum Antiviral Agent","author":"Smith","year":"1980"},{"key":"S0195941700065978_ref020","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/133.Supplement_2.A114"},{"key":"S0195941700065978_ref019","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/133.Supplement_2.A109"},{"key":"S0195941700065978_ref018","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/141.5.548"},{"key":"S0195941700065978_ref017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198601023140104"},{"key":"S0195941700065978_ref014","first-page":"83","volume-title":"Ribavirin: A Broad Spectrum Antiviral Agent","author":"Catlin","year":"1980"},{"key":"S0195941700065978_ref010","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198122020-00002"},{"key":"S0195941700065978_ref008","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.70.4.1174"},{"key":"S0195941700065978_ref007","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/14.suppl_A.27"},{"key":"S0195941700065978_ref012","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1977.tb21953.x"},{"key":"S0195941700065978_ref005","volume-title":"Synthesis and broad spectrum antiviral activity","author":"Witkowski","year":"1972"},{"key":"S0195941700065978_ref004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197903083001004"},{"key":"S0195941700065978_ref011","first-page":"402","article-title":"Ribavirin","volume":"255","author":"Patterson","year":"1975","journal-title":"Ann NY Acad Sci"},{"key":"S0195941700065978_ref002","doi-asserted-by":"publisher","DOI":"10.1016\/0091-7435(74)90010-3"},{"key":"S0195941700065978_ref001","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1542\/peds.36.1.21","article-title":"Acute respiratory disease in infancy and childhood: Present understanding and prospects for prevention","volume":"36","author":"Chanock","year":"1965","journal-title":"Pediatrics"},{"key":"S0195941700065978_ref003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197303082881005"},{"key":"S0195941700065978_ref009","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92060-9"},{"key":"S0195941700065978_ref028","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91152-1"},{"key":"S0195941700065978_ref016","unstructured":"ICN Pharmaceuticals: Virazole Product Monograph. Costa Mesa, CA, January 1986."},{"key":"S0195941700065978_ref031","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1542\/peds.72.5.613","article-title":"Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infections in infants","volume":"72","author":"Taber","year":"1983","journal-title":"Pediatrics"},{"key":"S0195941700065978_ref033","volume-title":"The Clinical Applications of Ribavirin","author":"Shulman","year":"1984"},{"key":"S0195941700065978_ref024","first-page":"215","volume-title":"Ribavirin: A Broad Spectrum Antiviral Agent","author":"Fernandez","year":"1980"},{"key":"S0195941700065978_ref006","doi-asserted-by":"publisher","DOI":"10.1126\/science.177.4050.705"},{"key":"S0195941700065978_ref015","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(79)91853-9"},{"key":"S0195941700065978_ref013","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(79)90058-5"}],"container-title":["Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0195941700065978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T20:25:48Z","timestamp":1656966348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0195941700065978\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1987,5]]}},"alternative-id":["S0195941700065978"],"URL":"https:\/\/doi.org\/10.1017\/s0195941700065978","relation":{},"ISSN":["0195-9417","2327-9451"],"issn-type":[{"value":"0195-9417","type":"print"},{"value":"2327-9451","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,5]]}}}